Monoclonal antibodies were ‘doing nothing’ against omicron. That’s why FDA pulled its authorization.
This post was originally published on this siteMonoclonal antibodies from drug-makers Regeneron and Eli Lilly have proven ineffective against the omicron variant of COVID-19.